drugset / Trial / NCT01614184

Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer

NCT01614184

Phase 1/2 Withdrawn University of Utah
NaSingle-groupOpen-labelTreatment

Summary

The study goal is to develop a new method of intraoperative lymphatic mapping with fluorescent contrast agents to improve the outcome of therapeutic breast cancer surgery.

Timeline

Start
2008-05
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluorescein Diagnostic / imaging agent 0.25 ml Other

Indications